{"id":237230,"date":"2020-06-11T08:31:18","date_gmt":"2020-06-11T06:31:18","guid":{"rendered":"http:\/\/intervacc.se\/?p=237230"},"modified":"2020-06-11T08:31:18","modified_gmt":"2020-06-11T06:31:18","slug":"intervacc-appoints-international-bacteriology-expert-as-chief-scientific-officer","status":"publish","type":"post","link":"https:\/\/intervacc.se\/en\/intervacc-appoints-international-bacteriology-expert-as-chief-scientific-officer\/","title":{"rendered":"Intervacc appoints international bacteriology expert as Chief Scientific Officer"},"content":{"rendered":"
\n

Stockholm 11 June 2020 \u2013 The Swedish biotechnology company Intervacc AB (publ), which is developing modern, effective and safe vaccines for animal health has appointed Dr. Andrew Waller as the new Chief Scientific Officer, CSO. The company has thus appointed an international leader in bacterial research in veterinary species to lead the company’s exciting development program for vaccines based on recombinant proteins. This appointment follows on the success of Intervacc\u2019s lead vaccine project against strangles in horses, Strangvac\u00ae<\/sup>, which was evaluated by Andrew\u2019s former laboratory at the Animal Health Trust. Dr. Andrew Waller will in his new role work together with the company’s co-founder Professor Jan-Ingmar Flock to lead the continued research to develop a new generation of vaccines within animal health.<\/p>\n<\/div>\n

Andrew Waller is one of the world\u2019s leading scientists in research related to streptococcal infections of animals with particular expertise on equine strangles. In addition to conducting the clinical trials of Strangvac\u00ae<\/sup>, his experience of the molecular genetics and epidemiology of these pathogens has informed the advice given to veterinarians and owners and led to the development of gold-standard diagnostic tests that are used around the world to prevent and resolve outbreaks. He will greatly contribute towards establishing Strangvac\u00ae<\/sup> on the market and he will strengthen Intervacc\u00b4s research to develop vaccines against Streptococcus suis<\/em> and Staphylococcus aureus<\/em>. As CSO he will lead the research, product development and clinical activities in close collaboration with our great research teams at Karolinska Institute and Swedish University of Agricultural Sciences (SLU).<\/p>\n

“I have known Andrew for many years and I am really glad that he has decided to join us in our future enterprises as new CSO and it will be great to collaborate with him even more closely,\u201d<\/em> Jan-Ingmar Flock says. \u201cIn addition to his knowledge of strangles, Andrew\u2019s appointment ensures continuity and provides modern bacteriological expertise within the company.\u201d<\/em><\/p>\n

\u201cI am excited that we have been able to recruit yet another strong and leading researcher to Intervacc. Andrew adds a fantastic energy and competence in the very important launch of our strangles vaccine, as well as in the further development of our promising pipeline projects\u201d<\/em> says Andreas Andersson CEO.<\/p>\n

\u201cThe technology at the heart of Strangvac\u00ae<\/sup> directs an immune response to simultaneously target an array of proteins used by invading bacteria and has enormous potential for the development of new vaccines with which to improve animal health\u201d<\/em> says Andrew Waller. \u201cI am delighted to be joining Intervacc at such an exciting period in the company\u2019s history\u201d<\/em><\/p>\n

For more information please contact:<\/strong>
\nAndreas Andersson, CEO
\nPhone: +46 (0)8 120 10 601, Cell: +46 (0)73 335 99 70
\nE-mail: andreas.andersson@intervacc.com<\/p>\n

The information was submitted for publication, through the agency of the contact person set out above on June 11, 2020, 08.30 CET.<\/em><\/p>\n

About Intervacc<\/strong>
\nIntervacc AB (publ) is a company within the Biotechnology sector. The Company\u00b4s main area is to develop modern sub-unit vaccines against economically important bacterial infections, within animal health. The company\u00b4s vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the company\u00b4s research and development work. The Intervacc share has been listed on the NASDAQ First North Growth Market since April 2017 with Eminova Fondkommission AB, adviser@eminova.se, +46 (0)8\u2013684 211 10 as Certified Adviser.<\/p>\n

About Karolinska Institutet<\/strong>
\nKarolinska Institutet is one of the world\u2019s leading medical universities. Its vision is to significantly contribute to the improvement of human health. Karolinska Institutet accounts for the single largest share of all academic medical research conducted in Sweden and offers the country\u2019s broadest range of education in medicine and health sciences. The Nobel Assembly at Karolinska Institutet selects the Nobel laureates in Physiology or Medicine. Visit the website at http:\/\/ki.se\/<\/p>\n

About Swedish University of Agricultural Sciences<\/strong>
\nThe Swedish University of Agricultural Sciences develops the understanding and sustainable use and management of biological natural resources. This is achieved by research, education and environmental monitoring and assessment. Research areas include agriculture, forestry, fishery, animal husbandry, veterinary medicine, environmental sciences and landscape architecture. Visit the website at https:\/\/www.slu.se\/en\/<\/p>\n

About the Animal Health Trust<\/strong>
\nThe Animal Health Trust is the UK\u2019s leading veterinary and scientific research charity, dedicated to the health and wellbeing of dogs, cats and horses. It aims to improve the health and welfare of horses, dogs and cats through research, but also provides specialist referral services and continuous education to vets. Visit the website at www.aht.org.uk<\/p>\n

Contact information for Certified Adviser<\/strong>
\nEminova Fondkommission AB
\nE-mail: adviser@eminova.se, Phone: +46 (0)8 \u2013 684 211 10<\/p>\n","protected":false},"excerpt":{"rendered":"

Stockholm 11 June 2020 \u2013 The Swedish biotechnology company Intervacc AB (publ), which is developing modern, effective and safe vaccines […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false},"categories":[27],"tags":[],"_links":{"self":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/posts\/237230"}],"collection":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/comments?post=237230"}],"version-history":[{"count":3,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/posts\/237230\/revisions"}],"predecessor-version":[{"id":237303,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/posts\/237230\/revisions\/237303"}],"wp:attachment":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/media?parent=237230"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/categories?post=237230"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/tags?post=237230"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}